Abstract
An isolated perfused rat heart preparation has been used in an attempt to define the mechanisms underlying the coronary vasoconstriction associated with the intraarterial infusion of cardioplegic solutions containing contaminant particles. Coronary infusion of commercially available intravenous solutions, compounded to create the St. Thomas' cardioplegic solution, resulted in a 40.3 +/- 1.9% decline in coronary flow rate at the end of a 20-minute period of infusion. Filtration of the solution through a 0.8 micron filter reduced this decline in flow rate to 23.4 +/- 2.3% of its control value. Inclusion of the 5HT2 receptor antagonist ketanserin (1.0 nanomoles/l), in the unfiltered cardioplegic solution, afforded the same protection as filtration. Inclusion of 5HT (0.1 micromole/l) in a filtered cardioplegic solution resulted in a reduction of coronary flow (49.7 +/- 1.9%) greater than that seen with the unfiltered solution. Studies with antagonists of the histamine receptor (mepyramine and cimetidine) and agonists and antagonists of adrenergic receptors suggested that, although involved in the control of vascular tone, these receptor systems are unlikely to be involved in the process of particle-induced vasoconstriction. Arguments are presented that 5 HT and its receptors may play a critical role and the hypothesis is advanced that particle-induced focal endothelial injury may be the primary lesion in a complex sequence of events leading to induction of transient vasoconstriction.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.